Application and products of metabolic markers in the preparation of products for monitoring PB nephrotoxicity

Through the use of metabolic logo and high -resolution mass spectrometry method in PB nephrotoxic monitoring products, the establishment of a variety of statistical models, solving the problem of lagging and unimpracting for PB kidney toxic monitoring in existing technologies, and realizing early and high sensitivity diagnosis.

CN118777488BActive Publication Date: 2025-01-28CHINA JAPAN FRIENDSHIP HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411281377.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2025-01-28
Estimated Expiration
2044-09-13

AI Technical Summary

Technical Problem

The prior art is difficult to effectively monitor and predict the nephrotoxicity of polymyxin B (PB). Traditional biochemical indicators have lag and lack of specificity, which limits the clinical application of PB.

Method used

In the preparation monitoring of PB kidney toxic products, metabolic logo uses high -resolution syndrome to detect metabolic logo in plasma and kidneys, such as L -carotic alkali, linoleic acid, hemolytic phospholipids, etc., to establish a diversified statistical model for early diagnosis.

Benefits of technology

The early diagnosis of early, high sensitivity, fast and convenient, and accurate and reliable diagnosis of PB renal toxicity provides a basis for clinical decision -making, and provides the basis for subsequent research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118777488B_ABST
    Figure CN118777488B_ABST
Patent Text Reader

Abstract

Disclosed is an application of a metabolic marker in the preparation of a product for monitoring PB nephrotoxicity and a product, which can be used to monitor PB nephrotoxicity with high sensitivity, rapidity and convenience, and accurate and reliable results. The application of this metabolic marker in the preparation of a product for monitoring PB nephrotoxicity, wherein the metabolic marker is one or more of the following substances: L-acetylcarnitine, linoleic acid, lysophospholipid 16:0, lysophospholipid 18:2, lysophospholipid 20:4, phospholipid 14:0 / 22:1, phospholipid 18:0 / 20:4, phospholipid 20:1 / 14:1, sphingolipid d18:0 / 24:1, sphingolipid d18:1 / 24:0.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Predictive renal safety biomarkers and biomarker signatures to monitor kidney function

    CN101679525A

  • Application of endogenous micromolecule substance to rapid detection on kidney toxicity

    CN104280478A